Wuhan Tongqian Medical Technology Co., Ltd., established on 2013-12-09, Business scope includes licensed projects:Class III medical device business;Inspection and testing service;Drug Wholesale(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Import and export;Technology Import and Export;Import and export agency;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Instrument sales;Glassware Sales;electronics sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Technologies Morphocell, Inc. is a Canadian private company that operates as a biotechnology company.\nThe company says this about itself: Founded in 2018, Morphocell is a Montreal-based regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating severe liver diseases.

GAIA BioMedicine, Inc., a technology-driven biopharmaceutical firm specialized in cell treatments and immunotherapies for intractable malignancies, was created in 2015 as a spin-off venture of Kyushu University. The firm name, GAIA, reflects the company's aim and vision as we fight intractable diseases with the strength of genes and the immune system as the rod of Asclepius, the Greek god of medicine.

Part of Southern Medical University, Zhujiang Hospital of Southern Medical University is a company headquartered in Guangzhou, China, that operates hospital.

Kangstem Biotech develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

Shandong Yiruite Biotechnology Co., Ltd., established on 2019-10-24, Business scope includes bioengineering and biomedical engineering,Technology development in the field of biomass energy,Technical Services,technology transfer;medical instruments,cell reactor(Development and application of gene diagnosis and treatment technology without human stem cells),Biological product(No vaccine),Research and development of computer software, hardware and auxiliary equipment,Production,Sales;Machinery and Equipment Leasing;Import and export of goods and technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)(The above operating items do not include items subject to special management measures for foreign investment access)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Kexian Medical Technology (Suzhou) Co., Ltd., established on 2019-03-06, Business scope includes technology development in the medical field,technology transfer,Technical consulting and related technical services;Purchase and sale of medical equipment.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

HepaHope, Inc. is a medical technology company, which engaged in researching, designing, patenting, manufacturing, and marketing life-saving medical technologies. The company is focused towards three primary markets, including artificial liver replacement, oncology testing and drug development. The company was founded by Sung-Soo Park in February 1999 and is headquartered in Irvine, CA.

Circe Biomedical, Inc. develops, produces, and commercializes bioartificial organ systems. It develops bioartificial organs from isolated mammalian cells and membranes for patients suffering from acute, end-stage liver failure. The company also develops PancreAssist System, an implantable, bioartificial pancreas for severe insulin-dependent diabetics. Circe Biomedical, Inc. was incorporated in 1999 and is based in Lexington, Massachusetts.

Develops proprietary medical devices and cell-based therapies

Guangdong Qianhui Biotechnology Co., Ltd., established on 2011-03-22, Business scope includes general business items:Biomedical Technology Development,Technical Services,technical consulting,technology transfer.,The licensing program is:none

Hoxan Corp. is a private company headquartered in Hokkaido, Japan. The firm manufactures, sells and exports fancy veneer, plywood, timber and other related products.

Kawasumi Laboratories, Inc. engages in the manufacture and sale of medical devices and pharmaceuticals. It operates through the Hemodialysis and Plasmapheresis; and Blood Transfusion and Endovascular segments. The Hemodialysis and Plasmapheresis segment develops, produces, and sells dialyzers, blood tubing lines, arteriovenous fistula needles, and isotonic sodium chloride solutions. It also offers removal of pathogenic factors from blood by extracorporeal circulation. The Blood Transfusion and Endovascular segment offers infusion therapy products, blood bags, apheresis kits, and intravenous sets. The company was founded by Takumi Kawano on December 1, 1954 and is headquartered in Tokyo, Japan.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

In addition to being a world-class automobile parts manufacturer, HYUNDAI WIA has Korea’s best technologies in machine-making-machines and machine tools. They supply innovative products with the highest quality and performance to automobile manufacturers around the world. From processing materials for basic automobile parts, HYUNDAI WIA manufactures automobile engines, turbo chargers, constant velocity joints, and complete power train products while actively responding to new automobile technology trends. Furthermore, they supply ultra-precision machine tools and factory automation lines to upgrade the quality capacity of global manufacturing companies.

Guojiutang Shandong Ejiao Co., Ltd., established on 2012-04-23, Business scope includes general items:Ejiao technology development,consultation service;Purchase and sale of agricultural and sideline products;Realtor.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Glue production(The validity period is subject to the license);Glue Sales;Production of Chinese Herbal Pieces;Sales of Chinese Herbal Pieces;food production;food sales;(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.

Daiichi Seiyaku Co., Ltd. engaged in the manufacture, sale research and development of medicine. The company was founded on October 1, 1915 and was headquartered in Tokyo, Japan.